Asset profile
CLE-100
Small molecule
Evidence outlook · lead readout
NCT06340958 · Adjunctive Treatment of Major Depressive Disorder (MDD)
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT06340958: The study randomized 99 participants to double-blind CLE-100 or placebo alongside standard antidepressants. Its clinical primary endpoint, change in MADRS score at 29 days, was not statistically significant (p=0.15), so the results provide real but inconclusive evidence of benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.